When scientists gave a substance called cyclocreatine to two types of cancer cells, one kind (from rat brain tumors) stored a modified version of it, but the other kind (from human ovarian tumors) didn't — meaning these cells handle the substance differently.

6

Pro

0

Against

Evidence from Studies

Supporting (1)

6

Community contributions welcome

6

Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy.

Cross-Sectional Study

Animal

1996 Jan

The study shows that when treated with cyclocreatine, one type of cancer cell turns it into a different molecule (phosphocyclocreatine), but another type doesn’t — just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy.

Score: 6

DOI: 10.1152/AJPCELL.1996.270.1.C160

Similar Assertions

Cyclocreatine kills brain tumor cells in rats by making them swell up, but it stops ovarian cancer cells in humans in a totally different way we don’t yet understand.

6

0

87%

Cyclocreatine slows down the growth of certain cancer cells in a lab dish, but it doesn’t harm their outer layer or energy supply — so it probably works in a different way.

6

0

84%